Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study.

Mammatas, L H

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study. [electronic resource] - Cancer chemotherapy and pharmacology 05 2020 - 931-940 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article

1432-0843

10.1007/s00280-020-04065-5 doi


Area Under Curve
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Monitoring--methods
Drug-Related Side Effects and Adverse Reactions--prevention & control
Female
Humans
Male
Middle Aged
Neoplasms--drug therapy
Protein Kinase Inhibitors--administration & dosage
Pulse Therapy, Drug--methods
Sorafenib--administration & dosage
Treatment Outcome